Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015


Financial Report: Biogen Idec 3Q

Published October 25, 2012
Biogen Idec

3Q Revenues: $1.4 billion (+6%)

3Q Earnings: $398.4 million (+13%)

YTD Revenues: $4.1 billion (+10%)

YTD Earnings: $1.1 billion (+16%)

Comments: Avonex sales were $736 million (+8%). Tysabri sales were $275 million (-1%). Rituxan revenues from an unconsolidated joint business arrangement were $288 million (+8%). Global in-market sales of Tysabri were $404 million (+3%), including $230 million in the U.S. Revenues from other products were $28 million, compared to $17 million in 3Q11. Royalty revenues were $47 million, compared to $52 million in 3Q11. In the quarter quarter, Biogen recognized a gain of $32 million related to the sale of rights related to Benlysta.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On